SEARCH

SEARCH BY CITATION

References

  • 1
    Ohtomo T, Sugamata Y, Ozaki Y et al . Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun 1999; 258: 58391.
  • 2
    Goto T, Kennel SJ, Abe M et al . A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 1994; 84: 192230.
  • 3
    Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451: 42530.
  • 4
    Ono K, Ohtomo T, Yoshida K et al . The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity. Mol Immunol 1999; 36: 38795.
  • 5
    Ozaki S, Kosaka M, Wakatsuki S, Abe M, Koishihara Y, Matsumoto T. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood 1997; 90: 317986.
  • 6
    Kawai S, Yoshimura Y, Iida S et al . Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models. Oncol Rep 2006; 15: 3617.
  • 7
    Powles R, Yong K, Sirohi B et al . Humanized anti-HM1.24 antibody (AHM): phase I study in patients with relapsed or refractory myeloma. Proceedings of the Japanese Multiple Myeloma Forum; 3 November 2003, Hokkaido, Japan.
  • 8
    Amato RJ. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 2005; 16: 715.
  • 9
    Patel PH, Chaganti RS, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 2006; 94: 61419.
  • 10
    Jemal A, Siegel R, Ward E et al . Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 7196.
  • 11
    Balch CM, Soong SJ, Gershenwald JE et al . Prognostic factors analysis of 17 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 362234.
  • 12
    Queirolo P, Acquati M, Kirkwood JM et al . Update: current management issues in malignant melanoma. Melanoma Res 2005; 15: 31924.
  • 13
    Keilholz U, Punt CJ, Gore M et al . Dacarbazine, cisplatin, and interferon-α-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005; 23: 674755.
  • 14
    Pavlick AC, Adams S, Fink MA, Bailes A. Novel therapeutic agents under investigation for malignant melanoma. Expert Opin Invest Drugs 2003; 12: 154558.
  • 15
    Ozaki S, Kosaka M, Wakahara Y et al . Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells. Blood 1999; 93: 392230.
  • 16
    Kawai S, Koishihara Y, Iida S et al . Construction of a conventional non-radioisotope method to quantify HM1.24 antigens: correlation of HM1.24 levels and ADCC activity of the humanized antibody against HM1.24. Leuk Res 2006; 30: 94956.
  • 17
    Liu Z, Smyth FE, Renner C, Lee FT, Oosterwijk E, Scott AM. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 2002; 51: 1717.
  • 18
    Bleumer I, Knuth A, Oosterwijk E et al . A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 2004; 90: 98590.
  • 19
    Ge Y, Dombkowski AA, LaFiura KM et al . Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood 2006; 107: 157082.